Table 4

ORsa for use of OCs among cases and HPV-positive controls

ControlsAdenocarcinomasSquamous cell carcinomas
nbIn situInvasiveIn situInvasive
Never used OC111.0c1.0c1.0c1.0c
Ever used OCs375.4 (0.7–43.4)1.3 (0.4–4.4)1.7 (0.5–6.2)1.2 (0.4–3.8)
 Former use273.1 (0.4–27.5)1.3 (0.4–4.1)1.8 (0.5–6.7)1.0 (0.3–3.2)
 Current used1017.1 (1.5–188.2)2.1 (0.4–11.9)1.6 (0.3–8.5)0.7 (0.1–3.6)
Duration of use
 2 years or less94.0 (0.4–44.3)1.5 (0.3–6.6)1.4 (0.3–7.2)1.1 (0.3–4.2)
 2–6 years124.8 (0.4–51.9)1.1 (0.2–5.2)3.8 (0.7–19.3)1.9 (0.4–8.4)
 >6 years166.2 (0.7–52.7)1.0 (0.2–4.2)1.1 (0.3–5.0)0.9 (0.2–3.7)
P (trend)P = 0.12P = 0.88P = 0.85P = 0.99
  • a Adjusted for age, ethnicity, income, HPV, lifetime number of sexual partners, and number of Pap smears.

  • b Excludes missing responses.

  • c Referent group for the column.

  • d Defined as OC use 12 months before diagnosis for cases and at reference date for controls.